Form 4: Astera Labs Director Manuel Alba Sells Shares Under 10b5-1 Trading Plan

Director Manuel Alba sold shares of Astera Labs (ALAB) on April 2nd and 3rd, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Manuel Alba, a director of Astera Labs, Inc. (ALAB), reported the sale of common stock on April 2nd and 3rd, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 31, 2024.
• On April 2nd, shares were sold at prices ranging from approximately $59.55 to $65.19.
• On April 3rd, shares were sold at prices ranging from approximately $55.42 to $59.54.
• The sales were made both directly and indirectly through Casa Alameda 2007, LLC and the Alba Trust.
• Following these transactions, Alba continues to beneficially own shares through these entities and directly.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports insider trading activity under a pre-existing plan. The sales themselves don't necessarily indicate a negative outlook, but could be perceived as such.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned well in advance and not based on any immediate insider knowledge.

Negatives

• The director is selling shares, which could be interpreted negatively by some investors.

Risks

• Continued sales by insiders could put downward pressure on the stock price.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Insider transactions are common and closely monitored, but without additional context, it's difficult to assess the broader implications for Astera Labs within the semiconductor industry.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially impacting the stock price in the short term.

Key Dates

Keywords

Astera Labs, ALAB, Manuel Alba, Form 4, insider trading, stock sale, Rule 10b5-1, Casa Alameda 2007, LLC, Alba Trust